Milbemycin oxime
 |
|
| Clinical data | |
|---|---|
| Routes of administration |
Oral |
| ATCvet code | |
| Pharmacokinetic data | |
| Bioavailability | 5–10% |
| Metabolism | Liver |
| Excretion | Biliary |
| Identifiers | |
| CAS Number | |
| UNII | |
| ECHA InfoCard | 100.205.451 |
| Chemical and physical data | |
| Formula | C31H43NO7 (30%) C32H45NO7 (70%) |
| Molar mass | 541.68 g/mol (30%) 555.702 g/mol (70%) |
  (what is this?)
|
|
Milbemycin oxime (trade name Interceptor, marketed by Novartis) is a veterinary drug from the group of milbemycins, used as a broad spectrum antiparasitic. It is active against worms (anthelmintic), insects (insecticide) and mites (miticide).
Like avermectins, milbemycins are products of fermentation by Streptomyces species. They have a similar mechanism of action, but a longer half-life than the avermectins. Milbemycin oxime is produced by Streptomyces hygroscopicus aureolacrimosus. It opens glutamate sensitive chloride channels in neurons and myocytes of invertebrates, leading to hyperpolarisation of these cells and blocking of signal transfer.
Milbemycin oxime is active against a broad spectrum of nematodes. Its miticide spectrum includes Sarcoptes and Demodex. The USA FDA approval for milbemycin oxime as formulated alone does not indicate insecticidal activity.
The drug is used for treatment and prevention of heartworm in dogs and cats, although it is less potent against heartworms than ivermectin.
The substance is often combined with other parasiticides to achieve a broader spectrum of action. Such products include:
...
Wikipedia